@article{JTD625,
author = {Giulio Metro and Vincenzo Minotti and Lucio Crinò},
title = {Years of sorafenib investigation in advanced non-small cell lung cancer: is there a ‘NExUS’ linking an unsuccessful treatment and a potentially active one?},
journal = {Journal of Thoracic Disease},
volume = {4},
number = {6},
year = {2012},
keywords = {},
abstract = {Sorafenib, a multi-targeted receptor tyrosine-kinase inhibitor (TKI) with a supposedly predominant anti-angiogenic activity (inhibition of vascular endothelial growth factor receptor-2, -3 and platelet-derived growth factor ß), has been the subject of extensive clinical research in advanced non-small cell lung cancer (NSCLC).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/625}
}